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Background & objectives: To estimate the efficacy of BCG in preventing tuberculosis over a 15-year
period, and also to assess the impact of infection with nontuberculous environmental mycobacteria
in a rural community in Chingleput district in Tamil Nadu in south India. We re-analysed the
15-year follow up data of a large randomized trial conducted earlier.
Methods: A double-blind randomized control trial was initiated in 1968, in which over 100,000
uninfected subjects with a normal radiograph were allocated to placebo, BCG in low dose (0.01 mg)
or BCG in high dose (1.0 mg); two widely used strains of BCG were employed, each in one half of
the vaccinated subjects. Sensitivity to purified protein derivative (PPD-B) was also determined.
The study population was followed for 15 yr by radiographic surveys of the total population once
every 2.5 yr, selective case finding in suspects once in 10 months, and investigation of those reporting
voluntarily with chest symptoms.
Results: Coverage by radiography was of the order of 80 per cent throughout, while coverage by
sputum examination of suspects was usually 90 per cent or above. The annual incidence of culture-
positive tuberculosis (irrespective of smear) was estimated to be 55 per 100,000, and neither strain
of BCG had any effect. The failure to protect was seen in both males and females, and in children
and adults. However, in a subset of over 40,000 subjects who were also nonreactors to PPD-B, BCG
had a low level of protection, i.e., 32 per cent (95% CI=3-52%), 29 per cent with the Danish strain
and 34 per cent with the French strain.
Interpretation & conclusion: Our findings reaffirm that BCG was of little value in preventing sputum-
positive cases of pulmonary tuberculosis.
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Based on a 15-year follow up of subjects in a large
randomized control trial in south India, we had
previously reported that BCG did not offer any
protection against adult forms of bacillary pulmonary
tuberculosis1. This finding applied not only to the
community at large, but also to the subset of subjects
who had no tuberculous infection at intake. We re-
examined the data in initially uninfected subjects
(induration of <8 mm to PPD-S) using better
statistical tools, and with special focus on children
and those that did not have a protective infection with
other environmental mycobacteria at intake. We also
identified successfully a subset of uninfected subjects
in those with a borderline induration to purified
protein derivative (PPD-S), i.e., 8-11 mm, and
extended the evaluation of BCG to the totality of
uninfected subjects. This report presents the findings
of this re-analysis.
Material & Methods
A double-blind randomized controlled trial was
initiated in 1968 in a large rural community in
Chingleput district in south India, to assess the
protective efficacy of BCG vaccination, employing
two strains of BCG. One of these was the Danish strain
1331 that has been used in India since 1966 and in the
British trial in 1950-1952 where it was found to be
highly effective, and the other was the widely used
French strain 1173 P 2. In this trial, all individuals in
the community who were aged >1 yr were tested with
3 international units (IU) of PPD-S, and 10 units of
PPD-B derived from Mycobacterium intracellulare.
PPD-S was supplied by the Antigen Production
Laboratory, Centers for Disease Control & Prevention
(CDC), Atlanta, Georgia, USA, during the first
6 months of the intake, and by the Statens Serum
Institut, Copenhagen, for the next two years. The
Antigen Production Laboratory, CDC Atlanta, USA,
supplied PPD-B. All subjects aged >10 yr had a
radiograph taken, and if it was abnormal, two sputum
specimens were examined by culture on Lowenstein-
Jensen (LJ) medium. All persons aged >1 month,
irrespective of their tuberculin sensitivity status, were
randomly allocated to a placebo, a low dose (0.01 mg)
or a high dose of BCG (0.1 mg), with half (selected at
random) receiving the Danish strain and the other half
the French strain. Intensive efforts were made to detect
all new cases of tuberculosis occurring over the next
15 yr, by means of total population surveys
(radiography followed by sputum examination of those
eligible) once in every 2.5 yr, selective case-finding
(once every 10 months) among those with an abnormal
radiograph or chest symptoms, and by setting up a
permanent diagnostic service to investigate those
reporting spontaneously with chest symptoms. The
details have been reported earlier1,2.
Those with an induration of 0-7 mm to PPD-S at
intake (i.e., no evidence of tuberculous infection) and
a normal radiograph constituted the primary
population for study. Employing dual testing with
PPD-S and PPD-B, it was concluded that only 2.7 per
cent of the persons with 8-11 mm to PPD-S (i.e., those
in whom the induration to PPD-S exceeded the
induration to PPD-B by at least 2 mm) had, in all
probability, a tuberculous infection. The rest were
regarded as uninfected at intake, and have been
included in a supplementary analysis of BCG efficacy.
For each 2.5 year period in each of the 3 series,
the population at risk was stratified by sex and age
(0-4, 5-9, 10-14, 15-24, 25-34, 35-44, 45-54 and >55
yr), and deaths and culture-positive cases were
estimated in each of the 16 (2 x 8) subgroups. These
estimates were then pooled to obtain the death rate
and the culture-positive incidence rate for the period.
Employing the estimates for the 6 periods in a life-
table analysis, the incidence of culture-positive
tuberculosis was determined for each series over the
15-year period.
Due to operational reasons, sputum was not
collected from 20 per cent of eligible persons in the
first resurvey (at 2.5 yr), from 9 per cent in the second
resurvey (at 5 yr), and from <5 per cent in the
subsequent resurveys. The losses were practically the
same in the 3 separate series (placebo, BCG low dose,
BCG high dose). The usual practice is to ignore the
potential yield from these, or presume that the
proportion of positive cultures would be the same as
in those examined. Instead, we estimated the probable
number of positive culture results by using the
relationship between radiographic status at the time
and the culture result from those who had both
examinations. The likelihood of a positive culture
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was significantly affected by the age at the time, and
also by sex in adults aged >15 yr. Among persons
with no sputum examination, the number in each
radiographic category was multiplied by the
appropriate sex and age-specific probability (of the
culture being positive) to estimate the number of
‘missed’ culture-positive cases; this was then added
to the observed number of cases to obtain a
consolidated total from which the incidence of
tuberculosis in all persons with a radiographic
examination was determined. Details and the
probabilities have already been reported3.
Statistical methods: Cox’s proportionate hazard
model4 was employed to assess the statistical
significance of the adjusted relative risk for BCG,
after allowing for age and sex.
Results
Study population: The eligible population for this
study, i.e., subjects with an induration of 0-7 mm to
PPD-S at intake and a normal radiograph, was 109863.
This number decreased substantially over the next
15 yr (Table I), mainly due to migration (27%); other
causes were death (5.5%) and development of
tuberculosis (0.4%). The number of persons allocated
was 36404 to placebo, 36459 to BCG low dose and
37000 to BCG high dose. The numbers in subsequent
periods also were similar in the three series (Table I),
as the losses due to migration were of the same order
(placebo 27.0%, low dose 26.6%, high dose 26.9%)
as also deaths (placebo 6.3%, low dose 6.5%, high
dose 6.2%). Further analysis showed that the losses
were similar in the three series in every period
(migration 4-7% in the first 10 yr, 10% during 10-
12.5 yr, and 14% in 12.5-15 yr; deaths 1.7% in 0-2.5
yr, 1.1-1.3% in subsequent periods). Also, the
distributions by age and sex of study population were
similar in the three series in every period.
Radiographic and sputum coverages: The coverage
by radiography was 83 per cent in the first three
periods, and 81, 79 and 77 per cent in the subsequent
three periods. The coverage by sputum was 80 per
cent in the first period, 91 per cent in the second period
and 95-96 per cent in subsequent periods. The findings
were very similar in the three series in every period.
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Incidence of tuberculosis: The average annual
incidence of culture-positive tuberculosis (whether
smear-positive or -negative) over the 15-year period
was virtually the same in the placebo, low dose and
high dose series, 54, 55 and 56 per 100,000,
respectively (Table II). The similarity was seen in
both males and females. In children of all ages, the
incidence appeared to be lower in the BCG series
(than in the placebo series) but in adults of all ages it
was higher; but none of the contrasts was statistically
significant. The incidence in the BCG series was
higher in the first 5 yr, but lower in subsequent
10 yr; again, none of the contrasts was significant.
The opposing directions of the differences and the
consistent nonsignificance of the contrasts suggested
that there was, in reality, no BCG effect, and that the
observed differences were due to chance.
Findings related to strain (Danish or French): There
was no difference between the French and Danish
Strains of BCG, the annual incidence of tuberculosis
(per 100,000) being 56 with Danish low dose, 54 with
French low dose, 58 with Danish high dose and 54
with French dose (and 54 with placebo).
Effect of nontuberculous mycobacterial infection at
intake: Considering first the placebo series (to avoid
confounding due to BCG), the incidence was 61 per
100,000 in 23158 subjects with a nontuberculous
mycobacterial infection at intake compared with 42
per 100,000 in 13246 without such an infection
(Relative risk, RR = 1.45). However, the former
group was considerably older, the proportions aged
>25 yr being 20 and 3 per cent, respectively, and those
aged 10-24 yr being 42 and 10 per cent. When
allowance was made for this difference, the adjusted
relative risk was significantly less than 1 (RR = 0.63;
P=0.02), indicating a protective effect of 37 per cent
(95% CI = 8 to 57%) from the nontuberculous
infection. In contrast, in the BCG series, the adjusted
RR for subjects with a nontuberculous infection was
0.92, close to 1 (P= 0.6).
Efficacy of BCG in subjects with and without a
nontuberculous protective infection: At intake, there
were 13246 placebo and 27096 BCG subjects who
had neither a tuberculous nor a protective
nontuberculous infection. Amongst these, the annual
incidence of tuberculosis was 42 per 100,000 in
placebo and 30 per 100,000 in the BCG series
(Table III), a protective effect of 29 per cent (adjusted
RR = 0.71, P=0.05). Multivariate analysis, allowing
for the effect of age and sex, yielded an efficacy
estimate of 32 per cent (95% CI=3 to 52%, P=0.03),
23 per cent for the low dose (95% CI= -15 to 49%,
P = 0.2) and 40 per cent for the high dose (95% CI =
8 to 61%, P =0.02). In a subset of children aged less
than 15 yr, the corresponding multivariate estimate
of protection was 36 per cent (P=0.03), while in those
aged less than 10 yr it was 26 per cent (P=0.18).
In subjects with a protective nontuberculous
infection, there was no evidence of BCG protective
effect (Table III); indeed, the suggestion was of a
deleterious effect (incidences of 61and 71 per
100,000 in placebo and BCG series), but this was
not statistically significant (adjusted RR=1.17,
P=0.14). In children aged less than 10 yr and those
aged less than 15 yr, there was no significant effect.
Inclusion of subset of uninfected subjects from those
with of 8-11 mm induration to PPD-S: Among persons
with an induration of 8-11 mm to PPD-S, 16780 were
classified as uninfected. Including these, the total
uninfected became 126643 (42105 placebo,
84538 BCG). Similar analyses were undertaken and
yielded the same conclusions, namely, no protection
from BCG, the incidence being 60 per 100,000 in both
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Table I. Numbers in present assessment of BCG vaccine*
Period Total Placebo BCG low dose BCG high dose
(yr) No. (%) No. (%) No. (%)
0 - 2.5 109863 36404 33.1 36459 33.2 37000 33.7
2.5-5 101487 33630 33.1 33638 33.1 34219 33.7
5-7.5 96238 31867 33.1 31940 33.2 32431 33.7
7.5-10 90826 30077 33.1 30114 33.2 30635 33.7
10-12.5 83339 27613 33.1 27655 33.2 28071 33.7
12.5-15 73923 24441 33.1 24570 33.2 24912 33.7
*Those with an induration of 0-7 mm to PPD-S at intake and a normal radiograph
Table II. Annual incidence of tuberculosis, by sex, age and BCG vaccination status (over a period of 15 years)
N Annual incidence (per 100,000) of tuberculosis*
(all 3 series) Placebo BCG series
Both doses Low dose High dose
Total 109863 54 56 55 56
Sex Male 50715 70 74 72 76
Female 59148 38 37 38 36
Age at 0-4 30710 20 16 17 15
intake (yr) 5-9 30271 43 33 33 33
0-9 60981 30 24 24 23
10-14 20186 85 80 70 90
15-24 13571 96 124 116 132
25-44 10776 83 102 109 95
>45 4349 91 104 128 80
Period (yr) 0-2.5 109863 12 21 22 19
2.5-5 101487 20 44 52 36
5-7.5 96238 44 33 26 40
7.5-10 90826 77 56 57 56
10-12.5 83339 84 72 79 65
12.5-15 73923 85 108 94 122
*Annual incidence of culture-positive tuberculosis, irrespective of smear.
None of the contrasts between the BCG and placebo series was significant
BCG and placebo series; in the subset of 40538
subjects with no protective nontuberculous infection
(13303 placebo, 27235 BCG), BCG reduced the
incidence by 27 per cent (P=0.06), from 42 to 30
per 100,000; the multivariate estimate of protection
was 32 per cent (P=0.04).
Discussion
In the 15-year follow up of the BCG trial1, the
incidence of tuberculosis was computed using the
person-years approach, which is better suited for a
steady incidence situation. However, the incidence of
tuberculosis is known to have decreased significantly
in the community during the study period3. We
therefore computed the incidence and death rate in
each period on the available subjects after stratifying
by age and sex, and combined these in a life table
analysis to obtain incidence rates of tuberculosis.
Further, rather than make arbitrary assumptions about
the missed yield from losses in sputum coverage (no
cases or same proportion as in examined subjects),
we utilized the strong association between the
radiographic result at the time and culture result to
predict the outcome. Such an approach had been
employed in the analysis of data from a national
sample survey in the Philippines5, and by us in earlier
publications3,6. On account of these modifications,
more realistic estimates of incidence have become
available for the comparisons between the BCG and
placebo series. In the earlier publication of the
15-year follow up1, 560 culture-positive cases were
observed in 1128696 person-years, i.e., an annual
incidence of 50 per 100,000. The missed cases due to
failure to examine sputum was estimated to be 46, and
adding these resulted in 606 new cases or an incidence
of 54 per 100,000, which differed only slightly from
the estimate of 55 per 100,000 in the current study.
This study reaffirmed strongly that BCG did not
offer any protection against adult forms of bacillary
pulmonary tuberculosis in the initially uninfected. This
conclusion applies to both males and females, as well
as adults of all ages and children. The conclusion with
respect to children was of special interest, as an earlier
report1 had suggested that over the 15-year period,
there was a low level of protection in those aged
<10 yr. That inference may be amended for the
following reasons. First, the incidence in the BCG
series was double than that in the placebo series in the
first 5 yr. Secondly, there were over 20,000 children
in each of the three series, and post facto computations
suggested that the sample size was large enough to
detect 40 per cent overall protection with 90 per cent
Power; in the event, the estimated protection was 26
per cent (95% CI= -15 to 53%), and statistically not
significant (P= 0.2). The simplest interpretation would
be that BCG offered no benefit to children in
preventing bacillary forms of tuberculosis.
One of the reasons advanced for the failure of
BCG was the influence of environmental
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Table III. Efficacy of BCG in persons with no tuberculous infection at intake, with and without infection with nontuberculous
mycobacteria
Age Number of persons Annual incidence of Protection** P Multivariate P
(yr) tuberculosis* from BCG (%) estimate
Placebo Low High BCG Placebo Low High BCG Low High BCG
BCG BCG (low+ BCG BCG (low+ BCG BCG (low+
high) high) high)
Infected with neither All 13246 13315 13781 27096 42 33 27 30 21 37 29 0.05 32 0.03
M. tuberculosis nor
nontuberculous 0-9 11537 11562 11866 23428 28 25 18 21 13 39 26 0.18 26 0.18
mycobacteria+ 0-14 12616 12638 13003 25641 36 26 21 24 28 43 35 0.03 36 0.03
Not infected with All 23158 23144 23219 46363 61 68 74 71 -17 -21 -19 0.10 -17 0.14
M. tuberculosis but infected with 0-9 8807 9063 8506 17569 33 24 31 27 32 11 22 0.32 22 0.31
nontuberculous mycobacteria++ 0-14 14466 14302 14142 28444 46 40 53 47 14 -11 1 0.93 3 0.86
*Annual incidence of culture-positive (irrespective of smear) tuberculosis per 100,000 over 15 years of follow up
**Estimate of protection, together with its statistical significance, was determined by Cox regression analysis
+S = 0-7, B<10; ++S = 0-7, B>10
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mycobacteria that are highly prevalent in tropical
countries and which are reported to confer a certain
amount of protection7,8, constituting a kind of
‘natural’ vaccination that resembles vaccination with
BCG. The magnitude of protection (based on
univariate analysis) was reported to be 60 per cent
over a 10-year period in the United Kingdom9, and
58 per cent over 3 yr in south India10. This hypothesis
received support from our study, as the prevalence
of nontuberculous infection was about 40 per cent
and the protective effect (based on multivariate
analysis allowing for the effects of age and sex) was
37 per cent. Next, in the subset of subjects who did
not have this initial nontuberculous infection, there
was evidence that BCG offered some protection,
23 per cent with the low dose, 38 per cent with the
high dose and 32 per cent for both doses combined.
The gradient with dose was suggestive and the
protection was just significant (P=0.04). Even so, the
findings may not have much public health importance
in this community, as this subset constituted less than
40 per cent of the uninfected population and the
protection was only 37 per cent.
It is thus concluded that BCG has had little effect
on preventing bacillary forms of tuberculosis, the
incidence of which must be brought down substantially
for tuberculosis control. The latter needs an efficient
diagnostic service and effective treatment programme,
as in the revised national tuberculosis control
programme (RNTCP) with the DOTS strategy.
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